查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999328

先進治療藥物（ATMP）CDMO市場：按產品類型、服務類型、治療領域、應用和最終用戶分類的全球市場預測，2026-2032年

Advanced Therapy Medicinal Products CDMO Market by Product Type, Service Type, Therapeutic Area, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，先進藥品 (ATMP) 的 CDMO 市值將達到 89.7 億美元，到 2026 年將成長到 104.3 億美元，到 2032 年將達到 284.6 億美元，複合年成長率為 17.92%。

主要市場統計數據
基準年 2025 89.7億美元
預計年份：2026年 104.3億美元
預測年份 2032 284.6億美元
複合年成長率 (%) 17.92%

簡明策略框架闡述了技術成熟度和營運需求如何重塑 CDMO 在細胞、基因和組織工程治療中的作用。

先進治療藥物（ATMP）的合約開發與生產（CDMO）產業處於科學創新與工業規模生物製程的交匯點。細胞療法、基因療法和組織工程的快速發展正在改變服務供應商的開發路徑和營運預期，這要求其在分析、製程開發、生產和法規遵從等各個方面進行能力重組。隨著申辦者從探索性研究轉向臨床和商業化供應，對能夠將深厚的生物程序專業知識與法規策略、品質系統和可擴展的生產平台相結合的合作夥伴的需求日益成長。

科學創新、監管預期和商業化壓力如何迫使CDMO擴大自身能力並建立更深的夥伴關係。

ATMP（先進治療藥物）領域的變革性變化源自於科學突破與商業性預期的融合，迫使CDMO（合約研發生產機構）超越傳統的生產服務模式。載體設計、細胞工程和支架技術的進步增加了製程的複雜性，同時也為實現以往無法達到的持續臨床療效開闢了道路。因此，CDMO必須平衡對細胞和載體分析的投資（以實現可靠的表徵和可比性）與對專用無塵室設施和一次性使用技術的投資。

為因應 2025 年關稅帶來的供應鏈和製造地策略調整，以維持連續性和成本效益。

將於2025年實施的新關稅措施增加了成本和複雜性，相關人員在採購原料、專用一次性組件和跨境製造服務時必須應對這些因素。關稅帶來的成本壓力促使贊助商和服務供應商重新評估供應鏈韌性，實現供應商多元化，並盡可能加快在地化策略。在某些情況下，製造商正在重新考慮其採購計劃，優先選擇來源透明且關稅合規記錄良好的供應商，以減少海關延誤和意外成本增加。

詳細的基於細分的分析表明，產品形式、服務範圍、治療領域、臨床階段和最終用戶概況如何定義差異化的 CDMO 價值提案。

細分市場洞察揭示了不同的需求促進因素和能力要求，這些因素應指南產品組合開發和市場策略。根據產品類型，該領域包括細胞治療產品、基因治療產品和組織工程產品。在細胞治療領域，需求分為非幹細胞療法和幹細胞療法；在基因治療領域，需求又分為細胞株療法和體細胞基因療法。每種療法都有其獨特的生產和監管方面的考量。這些模式差異會影響供應商必須提供的分析類型和規模、療效檢測以及出貨測試，以降低臨床開發中的風險。

區域製造生態系統和監管條件如何影響先進治療藥物的供應商選擇和生產能力的地理分佈

區域趨勢正在重塑贊助商進行研發和確保商業性供應的地點，地理優勢和限制影響著供應商的專業化方向和客戶合作模式。在美洲，對靈活製造和先進分析的投資正在打造一個支持規模化生產的中心，強調早期計畫快速過渡到臨床試驗。人才集中和完善的監管管道使該地區對複雜治療方法的研發極具吸引力，但高昂的營運成本促使混合模式的出現，即將國內生產能力與非核心流程的海外生產相結合。

對供應商策略的評估表明，能力整合、有針對性的專業化和策略夥伴關係正在塑造 CDMO 服務的競爭優勢。

在企業層面，發展趨勢聚焦於能力整合、平台擴充性以及連結科學研發和商業化準備的策略夥伴關係。主要企業正投資建構端到端的能力體系，將嚴謹的分析測試、先進的製程開發和監管支援相結合，為複雜的細胞和基因治療項目提供一致的價值提案。這些投資通常與有針對性的合作夥伴關係、技術授權或共同開發契約相結合，從而加速獲取專用載體、細胞增殖平台和療效評估技術。

為先進治療性CDMO各領域的領導者提供切實可行的策略，以增強韌性、擴展能力並建立更深入、風險共用的夥伴關係。

產業領導者應採取前瞻性策略，兼顧短期業務永續營運和長期能力建構。當務之急包括：提高關鍵原料和一次性耗材的供應鏈透明度；正式製定多通路採購策略以降低關稅和物流風險；以及實施符合多個司法管轄區監管要求的健全庫存管理和批次追蹤機制。同時，增加對先進分析技術和功效測試的投資，將有助於提高批次放行的可比性和可信度，並減少下游監管方面的阻力。

我們採用嚴謹的混合方法研究途徑，結合一手訪談、技術文獻綜述和能力映射，為決策者提供檢驗的見解。

本報告的分析整合了第一手和第二手資料，旨在提供基於實證的洞察，深入剖析醫療服務提供者的能力、市場動態和營運趨勢。第一手資料包括對處於研發階段的贊助公司的高級領導、生產主管、製程科學家和監管專家的結構化訪談，從而獲取關於營運重點和夥伴關係標準的第一手觀點。二級資訊來源包括同行評審文獻、監管指導文件和技術白皮書，對與先進治療方法相關的技術和合規趨勢進行了多角度的檢驗。

策略挑戰在於如何協調科學平台、製造系統和監管遠見，以支持先進治療計畫的整個生命週期。

在先進治療方法領域，CDMO（合約研發生產機構）的策略日益注重建立穩固的夥伴關係卓越的科學研究實力、嚴謹的生產製造和前瞻性的監管策略相結合，以降低專案風險並加速患者獲得治療。日益複雜的技術、不斷變化的關稅趨勢以及區域生產環境等多重壓力，使得申辦方和供應商都必須採用靈活的、基於平台的模式，並深化從基礎研究到規模化生產的合作。將分析、模組化設施和合規基礎設施的投資與目標治療領域的專業知識相結合，能夠幫助相關人員在整個研發階段提高可預測性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 先進治療藥物（ATMP）CDMO市場：依產品類型分類

  • 細胞治療產品
    • 非幹細胞療法
    • 幹細胞療法
  • 基因治療產品
    • 生殖細胞療法
    • 體細胞基因治療
  • 組織工程產品

第9章 先進治療藥物（ATMP）CDMO市場：依服務類型分類

  • 分析測試和品管
  • 製造服務
  • 流程開發服務
  • 監管和合規支持

第10章 先進治療藥物（ATMP）CDMO市場：依治療領域分類

  • 循環系統
  • 皮膚科
  • 血液學
  • 神經病學
  • 腫瘤學

第11章 先進治療藥物（ATMP）CDMO市場：依應用領域分類

  • 臨床階段
  • 商業階段

第12章 先進治療藥物（ATMP）CDMO市場：依最終用戶分類

  • 學術和研究機構
  • 生物製藥公司

第13章 先進治療藥物（ATMP）CDMO市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 先進治療藥物（ATMP）CDMO市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 先進治療藥物（ATMP）CDMO市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國先進治療藥物（ATMP）CDMO市場

第17章：中國先進治療藥物（ATMP）CDMO市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abzena
  • Advanced Therapies, LLC
  • AGC Inc.
  • Aldevron
  • Almac Group
  • Bio Elpida by Polyplus
  • BlueReg
  • Catalent Inc.
  • CELONIC Group
  • CGT Catapult
  • Charles River Laboratories International, Inc.
  • Coriolis Pharma Research GmbH
  • Curia Global, Inc.
  • Eurofins Scientific SE
  • FUJIFILM Diosynth Biotechnologies
  • Lonza Group
  • Minaris Regenerative Medicine
  • Oxford Biomedica PLC
  • Patheon by Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Rentschler Biopharma SE
  • REPROCELL Inc.
  • RoslinCT
  • Samsung Biologics
  • VIVEBIOTECH SL
Product Code: MRR-3A2E844FDCF6

The Advanced Therapy Medicinal Products CDMO Market was valued at USD 8.97 billion in 2025 and is projected to grow to USD 10.43 billion in 2026, with a CAGR of 17.92%, reaching USD 28.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.97 billion
Estimated Year [2026] USD 10.43 billion
Forecast Year [2032] USD 28.46 billion
CAGR (%) 17.92%

A concise strategic framing of how technological maturation and operational demands are reshaping CDMO roles for cell, gene, and tissue engineered therapeutics

The advanced therapy medicinal products (ATMP) contract development and manufacturing organization (CDMO) sector sits at the intersection of scientific innovation and industrial-scale bioprocessing. Rapid advances in cell therapy, gene therapy, and tissue engineering are shifting development pathways and operational expectations for service providers, triggering a reframing of capabilities across analytical, process development, manufacturing, and regulatory functions. As sponsors progress from exploratory research to clinical and commercial supply, they increasingly require partners who can integrate deep bioprocess expertise with regulatory strategy, quality systems, and scalable manufacturing platforms.

This executive summary synthesizes current dynamics shaping provider selection, investment priorities, and competitive differentiation. It emphasizes how technological maturation, regulatory evolution, and supply chain realities are driving CDMOs to expand service breadth while enhancing specialization. The narrative connects scientific trends to operational imperatives, offering leaders a clear perspective on where to align resources, which capability gaps to prioritize closing, and how to position organizations to support both small molecule-free biologics and complex engineered modalities. The intent is to help decision-makers convert technical insights into practical strategic actions that reduce program risk and accelerate timelines without compromising quality or compliance.

How converging scientific innovation, regulatory expectations, and commercialization pressures are compelling CDMOs to expand capabilities and form deeper partnerships

Transformative shifts in the ATMP landscape are driven by the confluence of scientific breakthroughs and commercial expectations, pressing CDMOs to evolve beyond traditional manufacturing service models. Advances in vector design, cell engineering, and scaffold technologies are increasing process complexity while simultaneously opening routes to durable clinical responses that were previously unattainable. As a result, CDMOs must balance investments in specialized cleanroom architectures and single-use technologies with investments in cell and vector analytics that enable robust characterization and comparability.

Concurrently, payers and regulators are emphasizing long-term evidence generation and supply consistency, which motivates sponsors to select partners capable of supporting lifecycle strategies from early clinical development through commercialization. This dynamic is fostering deeper strategic alliances where CDMOs participate in platform development, regulatory filing support, and post-market manufacturing assurance. The shift places a premium on flexible capacity, data integrity, and cross-functional project governance, with successful providers demonstrating an ability to de-risk development pathways while optimizing cost and time to clinic.

Navigating the 2025 tariff-driven recalibration of supply chains and manufacturing location strategies to maintain continuity and cost-effectiveness

The imposition of new tariff measures in 2025 has introduced an additional cost and complexity vector that stakeholders must navigate in sourcing raw materials, specialized single-use components, and cross-border manufacturing services. Tariff-driven cost pressures have prompted sponsors and service providers to reassess supply chain resilience, diversifying supplier bases and accelerating localization strategies where feasible. In some cases, manufacturers are reconfiguring procurement plans to prioritize vendors with transparent origin and tariff compliance histories to reduce customs delays and unexpected cost pass-throughs.

Moreover, the tariff environment has influenced strategic decisions around where to locate manufacturing capacity for clinical and commercial supply. Sponsors are increasingly weighing the trade-offs between centralized high-capacity sites versus distributed regional manufacturing models that can mitigate tariff exposure and shorten logistical pathways. Regulatory dossiers and quality systems must be adjusted to reflect multi-jurisdictional production plans, and CDMOs are responding by enhancing customs expertise, implementing robust inventory buffers, and developing cost-allocation frameworks that preserve program economics while maintaining supply reliability.

A nuanced segmentation-driven lens showing how product modalities, service scopes, therapeutic areas, application stages, and end-user profiles define differentiated CDMO value propositions

Segmentation insights reveal differentiated demand drivers and capability requirements that should guide portfolio development and go-to-market strategies. Based on Product Type, the landscape includes Cell Therapy Products, Gene Therapy Products, and Tissue Engineered Products; within cell therapies, demand separates between Non-stem Cell Therapy and Stem Cell Therapy, while gene therapy distinctions arise between Germline Therapy and Somatic Gene Therapy, each pathway carrying unique manufacturing and regulatory considerations. These modality distinctions influence the type and scale of analytics, potency assays, and release testing that providers must offer to de-risk clinical progression.

Based on Service Type, service expectations encompass Analytical Testing & Quality Control, Manufacturing Services, Process Development Services, and Regulatory & Compliance Support, and the most competitive providers integrate these capabilities to provide seamless technology transfer and comparability assessments. Based on Therapeutic Area, the sector spans Cardiology, Dermatology, Hematology, Neurology, and Oncology, with oncology and hematology programs frequently demanding accelerated timelines, complex release criteria, and higher regulatory scrutiny. Based on Application, differentiation between Clinical Stage and Commercial Stage use cases requires flexibility in batch size, facility qualification, and supply chain robustness. Based on End-User, the market engages both Academic & Research Institutes and Biopharmaceutical Companies, which present divergent needs around cost sensitivity, regulatory sophistication, and expectations for long-term manufacturing partnerships.

Taken together, these segmentation axes show that successful service providers must architect modular offerings that can be configured to meet modality-specific analytical demands, therapeutic area nuances, and the distinct operational rhythms of early-stage researchers versus commercial sponsors. This segmentation-informed approach enables targeted investment in platform technologies and quality infrastructures that align with customer priorities and regulatory pathways.

How regional manufacturing ecosystems and regulatory landscapes are influencing sourcing choices and the geographical distribution of advanced therapy production capacity

Regional dynamics are reshaping where sponsors elect to conduct development and secure commercial supply, with geographic strengths and constraints influencing provider specialization and client engagement models. In the Americas, investment into flexible manufacturing and advanced analytics is creating hubs that emphasize speed to clinic for early-phase programs and support for scale-up activities. Talent concentration and established regulatory pathways make the region attractive for complex modality development, but high operational costs incentivize hybrid models that combine domestic capacity with offshore manufacturing for non-core processes.

In Europe, Middle East & Africa, regulatory harmonization efforts and incentives in several jurisdictions support a diverse provider ecosystem that blends academic spinouts with industrial-scale CDMOs. This regional tapestry fosters collaborative innovation but also requires close attention to cross-border regulatory alignment and localized compliance requirements. In Asia-Pacific, rapid capacity expansion, competitive manufacturing cost structures, and growing scientific talent pools are driving an increasing share of clinical and commercial manufacturing activities, though sponsors must carefully evaluate quality standards and supply chain traceability when engaging new partners.

These regional distinctions encourage sponsors to adopt multi-regional sourcing strategies that balance speed, cost, and regulatory security. Providers that can demonstrate validated processes across jurisdictions, harmonized quality systems, and robust logistics will be better positioned to capture cross-border demand and to support clients pursuing global clinical development and commercialization pathways.

An assessment of provider strategies showing how capability consolidation, targeted specialization, and strategic partnerships are shaping competitive advantage in CDMO services

Company-level dynamics are centered on capability integration, platform scalability, and strategic partnerships that bridge scientific development with commercial readiness. Leading providers are investing in end-to-end capability stacks, combining rigorous analytical testing, advanced process development, and regulatory support to present cohesive value propositions for complex cell and gene therapy programs. These investments often pair with targeted alliances, technology licenses, or joint development agreements that accelerate access to specialized vectors, cell expansion platforms, and potency assay technologies.

At the same time, the competitive field includes specialist providers that maintain high-value niches, such as vector manufacturing or bespoke tissue engineering services, which can be highly attractive to sponsors seeking domain-specific expertise. Mergers and acquisitions continue to be a strategic lever for scaling capacity and absorbing specialized know-how, while organic investments in single-use infrastructure and digital quality systems enhance operational responsiveness. For sponsors, the optimal partner selection balances an assessment of technical fit, track record in regulatory submissions, and the provider's governance model for risk sharing and traceability during technology transfers.

Actionable strategies for leaders to enhance resilience, scale capabilities, and forge deeper, risk-aligned partnerships across the advanced therapy CDMO continuum

Industry leaders should adopt a proactive agenda that balances near-term operational resilience with longer-term capability building. Immediate priorities include strengthening supply chain transparency for critical raw materials and single-use consumables, formalizing multi-sourcing strategies to mitigate tariff and logistics exposure, and implementing robust inventory and batch-tracking mechanisms that align with multi-jurisdictional regulatory expectations. Parallel investments in advanced analytics and potency assays will improve comparability and batch release confidence, reducing downstream regulatory friction.

Over the medium term, organizations should prioritize modular facility design and platform standardization to enable rapid scaling from clinical to commercial manufacture. Cultivating strategic partnerships with vector specialists, academic translation centers, and technology licensors can accelerate time-to-clinic while distributing development risk. Leadership should also invest in workforce development programs that build cross-disciplinary expertise in process development, regulatory affairs, and quality systems. Finally, aligning commercial engagement models to offer outcome-linked milestones or shared risk arrangements can differentiate providers and foster deeper, longer-term sponsor relationships that support streamlined development and market entry.

A rigorous mixed-method research approach integrating primary interviews, technical literature review, and capability mapping to deliver validated insights for decision-makers

The analysis underpinning this report synthesizes primary and secondary inputs to produce an evidence-based view of provider capabilities, market dynamics, and operational trends. Primary research included structured interviews with senior leaders across development-stage sponsors, manufacturing executives, process scientists, and regulatory specialists to capture first-hand perspectives on operational priorities and partnership criteria. Secondary sources comprised peer-reviewed literature, regulatory guidance documents, and technical white papers to triangulate technological and compliance trends relevant to advanced modalities.

Analytical methods combined qualitative thematic analysis of interview transcripts with capability mapping and scenario-based risk assessment to evaluate how tariff changes, regional dynamics, and modality complexity influence sourcing and manufacturing strategies. Comparative provider profiling emphasized observable metrics such as facility type, service breadth, historical regulatory interactions, and documented platform technologies. Where possible, the methodology prioritized verifiable, primary-source evidence and cross-validation to ensure findings are robust and actionable for decision-makers seeking to align manufacturing strategies with clinical and commercial objectives.

Strategic imperatives for aligning scientific platforms, manufacturing readiness, and regulatory foresight to support the full lifecycle of advanced therapy programs

Advanced therapy CDMO strategy is increasingly about orchestrating scientific excellence, manufacturing rigor, and regulatory foresight into cohesive partnerships that reduce program risk and accelerate patient access. The combined pressures of technological complexity, tariff dynamics, and regional manufacturing evolution make it imperative for both sponsors and providers to adopt flexible, platform-based approaches and to deepen collaborations that bridge bench science to scalable production. By aligning investments in analytics, modular facilities, and compliance infrastructure with targeted therapeutic area expertise, stakeholders can improve predictability across development stages.

Decision-makers who prioritize transparent supply chains, validated multi-regional capabilities, and shared-risk commercial models will be better positioned to navigate uncertainty while capturing the value of advanced modalities. The path forward is one of selective specialization complemented by interoperable platforms, enabling providers to support the full lifecycle of ATMP programs while maintaining quality and regulatory alignment. This strategic orientation will determine which organizations can reliably serve the complex needs of next-generation therapeutics and sustain long-term partnerships with sponsors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Advanced Therapy Medicinal Products CDMO Market, by Product Type

  • 8.1. Cell Therapy Products
    • 8.1.1. Non-stem Cell Therapy
    • 8.1.2. Stem Cell Therapy
  • 8.2. Gene Therapy Products
    • 8.2.1. Germline Therapy
    • 8.2.2. Somatic Gene Therapy
  • 8.3. Tissue Engineered Products

9. Advanced Therapy Medicinal Products CDMO Market, by Service Type

  • 9.1. Analytical Testing & Quality Control
  • 9.2. Manufacturing Services
  • 9.3. Process Development Services
  • 9.4. Regulatory & Compliance Support

10. Advanced Therapy Medicinal Products CDMO Market, by Therapeutic Area

  • 10.1. Cardiology
  • 10.2. Dermatology
  • 10.3. Hematology
  • 10.4. Neurology
  • 10.5. Oncology

11. Advanced Therapy Medicinal Products CDMO Market, by Application

  • 11.1. Clinical Stage
  • 11.2. Commercial Stage

12. Advanced Therapy Medicinal Products CDMO Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Biopharmaceutical Companies

13. Advanced Therapy Medicinal Products CDMO Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Advanced Therapy Medicinal Products CDMO Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Advanced Therapy Medicinal Products CDMO Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Advanced Therapy Medicinal Products CDMO Market

17. China Advanced Therapy Medicinal Products CDMO Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abzena
  • 18.6. Advanced Therapies, LLC
  • 18.7. AGC Inc.
  • 18.8. Aldevron
  • 18.9. Almac Group
  • 18.10. Bio Elpida by Polyplus
  • 18.11. BlueReg
  • 18.12. Catalent Inc.
  • 18.13. CELONIC Group
  • 18.14. CGT Catapult
  • 18.15. Charles River Laboratories International, Inc.
  • 18.16. Coriolis Pharma Research GmbH
  • 18.17. Curia Global, Inc.
  • 18.18. Eurofins Scientific SE
  • 18.19. FUJIFILM Diosynth Biotechnologies
  • 18.20. Lonza Group
  • 18.21. Minaris Regenerative Medicine
  • 18.22. Oxford Biomedica PLC
  • 18.23. Patheon by Thermo Fisher Scientific Inc.
  • 18.24. Recipharm AB
  • 18.25. Rentschler Biopharma SE
  • 18.26. REPROCELL Inc.
  • 18.27. RoslinCT
  • 18.28. Samsung Biologics
  • 18.29. VIVEBIOTECH S.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NON-STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SOMATIC GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGULATORY & COMPLIANCE SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)